Menu
GeneBe

JARID2

jumonji and AT-rich interaction domain containing 2, the group of AT-rich interaction domain containing|Iron (II) and 2-oxoglutarate dependent oxygenases

Basic information

Region (hg38): 6:15246068-15522042

Previous symbols: [ "JMJ" ]

Links

ENSG00000008083NCBI:3720OMIM:601594HGNC:6196Uniprot:Q92833AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • syndromic intellectual disability (Supportive), mode of inheritance: AD
  • developmental delay with variable intellectual disability and dysmorphic facies (Strong), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Developmental delay with variable intellecutal disability and dysmorphic faciesADGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingCraniofacial; Musculoskeletal; Neurologic33077894; 35533077; 35887345

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the JARID2 gene.

  • Inborn genetic diseases (58 variants)
  • not provided (53 variants)
  • JARID2-related condition (6 variants)
  • Developmental delay with variable intellectual disability and dysmorphic facies (5 variants)
  • Neurodevelopmental disorder (3 variants)
  • JARID2-associated Neurodevelopmental disorder (2 variants)
  • not specified (1 variants)
  • Intellectual disability, mild (1 variants)
  • Autism;Speech apraxia;Intellectual disability;Stereotypic movement disorder (1 variants)
  • JARID2-related Neurodevelopmental syndrome (1 variants)
  • Autosomal dominant non-syndromic intellectual disability (1 variants)
  • JARID2-related Neurodevelopmental Disorder (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the JARID2 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
7
clinvar
11
clinvar
18
missense
1
clinvar
71
clinvar
15
clinvar
4
clinvar
91
nonsense
2
clinvar
2
start loss
0
frameshift
5
clinvar
2
clinvar
1
clinvar
8
inframe indel
0
splice donor/acceptor (+/-2bp)
2
clinvar
2
splice region
1
1
3
5
non coding
0
Total 5 5 74 22 15

Variants in JARID2

This is a list of pathogenic ClinVar variants found in the JARID2 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
6-15246549-GAA-G Autosomal dominant non-syndromic intellectual disability Likely pathogenic (Feb 10, 2022)1339774
6-15246570-A-C Inborn genetic diseases Uncertain significance (May 18, 2023)2532222
6-15246574-A-C Inborn genetic diseases Uncertain significance (Jul 05, 2023)2609491
6-15374124-G-A JARID2-related disorder Uncertain significance (Oct 28, 2022)2635867
6-15374141-T-A Uncertain significance (Dec 19, 2022)2505818
6-15374229-C-T Inborn genetic diseases Uncertain significance (Sep 13, 2023)2623599
6-15374244-CTG-C Neurodevelopmental disorder Pathogenic (Apr 02, 2021)1064851
6-15410322-G-A Inborn genetic diseases Uncertain significance (Nov 17, 2023)3112222
6-15410332-C-T Uncertain significance (May 09, 2023)2662150
6-15452030-G-T Speech apraxia;Autism;Stereotypic movement disorder;Intellectual disability Likely pathogenic (Jan 29, 2021)1803984
6-15452072-A-G JARID2-related disorder Benign (Jul 11, 2019)3049562
6-15452075-G-C JARID2-related disorder Uncertain significance (Sep 13, 2023)2631267
6-15452093-AC-A Inborn genetic diseases Pathogenic (Sep 09, 2021)2387170
6-15452098-C-G Uncertain significance (Jul 01, 2023)2734527
6-15452120-C-A Inborn genetic diseases Uncertain significance (Feb 17, 2022)2277592
6-15452127-A-C JARID2-related disorder Uncertain significance (Jan 25, 2024)3029868
6-15452170-T-C JARID2-related disorder Uncertain significance (Sep 01, 2023)2631027
6-15468547-C-T Inborn genetic diseases Uncertain significance (Jul 25, 2023)2613635
6-15468593-A-G Inborn genetic diseases Uncertain significance (Aug 10, 2021)2412402
6-15468604-G-C Uncertain significance (Sep 17, 2021)1434278
6-15468627-A-G Benign (Dec 31, 2019)709230
6-15468630-C-T Likely benign (Mar 06, 2018)790347
6-15468645-C-G JARID2-related disorder Benign (Jul 15, 2021)1302851
6-15468645-C-T Benign/Likely benign (Jun 01, 2022)788355
6-15468697-A-G Uncertain significance (Feb 24, 2020)1315351

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
JARID2protein_codingprotein_codingENST00000341776 18275726
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
1.000.00000562125739091257480.0000358
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense2.695757870.7310.00005108125
Missense in Polyphen117243.770.479962466
Synonymous-2.123833341.150.00002412482
Loss of Function6.31555.90.08940.00000291654

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00002890.0000289
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.00006170.0000615
Middle Eastern0.000.00
South Asian0.000.00
Other0.0003280.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Regulator of histone methyltransferase complexes that plays an essential role in embryonic development, including heart and liver development, neural tube fusion process and hematopoiesis. Acts by modulating histone methyltransferase activity and promoting the recruitment of histone methyltransferase complexes to their target genes. Binds DNA and mediates the recruitment of the PRC2 complex to target genes in embryonic stem cells. Does not have histone demethylase activity but regulates activity of various histone methyltransferase complexes. In embryonic stem cells, it associates with the PRC2 complex and inhibits trimethylation of 'Lys-27' of histone H3 (H3K27me3) by the PRC2 complex, thereby playing a key role in differentiation of embryonic stem cells and normal development. In cardiac cells, it is required to repress expression of cyclin-D1 (CCND1) by activating methylation of 'Lys-9' of histone H3 (H3K9me) by the GLP1/EHMT1 and G9a/EHMT2 histone methyltransferases. Also acts as a transcriptional repressor of ANF via its interaction with GATA4 and NKX2-5. Participates in the negative regulation of cell proliferation signaling. {ECO:0000269|PubMed:20075857}.;
Pathway
Signaling pathways regulating pluripotency of stem cells - Homo sapiens (human);Endoderm Differentiation;Mesodermal Commitment Pathway;Interactome of polycomb repressive complex 2 (PRC2);Epigenetic regulation of gene expression;Gene expression (Transcription);PRC2 methylates histones and DNA (Consensus)

Recessive Scores

pRec
0.182

Intolerance Scores

loftool
0.0413
rvis_EVS
-1.74
rvis_percentile_EVS
2.42

Haploinsufficiency Scores

pHI
0.983
hipred
Y
hipred_score
0.825
ghis
0.561

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.955

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Jarid2
Phenotype
normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; embryo phenotype; liver/biliary system phenotype; respiratory system phenotype; immune system phenotype; skeleton phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); growth/size/body region phenotype; endocrine/exocrine gland phenotype; cellular phenotype; homeostasis/metabolism phenotype; muscle phenotype;

Gene ontology

Biological process
negative regulation of transcription by RNA polymerase II;liver development;chromatin remodeling;central nervous system development;negative regulation of cardiac muscle hypertrophy;histone demethylation;negative regulation of histone methylation;negative regulation of gene expression, epigenetic;negative regulation of transcription, DNA-templated;spleen development;thymus development;stem cell differentiation;positive regulation of histone H3-K9 methylation;negative regulation of cardiac muscle cell proliferation;cellular response to leukemia inhibitory factor
Cellular component
nucleus;nucleoplasm;mitochondrion;histone methyltransferase complex;ESC/E(Z) complex
Molecular function
RNA polymerase II regulatory region sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;chromatin binding;transcription factor binding;histone demethylase activity;histone demethylase activity (H3-trimethyl-K4 specific)